M
Über

Meg Krench joined Sanofi Ventures in 2021 with a background in biotech investing and business development. Previously, she worked as part of the External Innovation team at Vertex Pharmaceuticals and at RA Capital, a crossover investment fund. Meg currently serves as a director for Normunity and as an observer for several companies including Draig Therapeutics, Eligo Bioscience, Korsana Biosciences, Quralis, and a stealth immunology company. Meg also supported Sanofi Ventures’ investment in Aliada Therapeutics before its acquisition by Abbvie for $1.4 billion. Meg holds a Ph.D. in Neuroscience from Massachusetts Institute of Technology and a B.S. with Honors in Neuroscience from The Pennsylvania State University. She is also co-chair of the Board of Directors for the New England Venture Network.

Schwerpunkte

BioTech

Region

📍 Ansässig in Cambridge

Verifizierte Kontakte & Outreach Agenten

Direktes E-Mail-Muster

[email protected] | [email protected]

KI Outreach Agenten Pitch Writer

Erstelle personalisierte Anschreiben basierend auf den genauen Investitionskriterien...

Direkten Partnerkontakt freischalten

Erhalte Zugriff auf verifizierte Kontakte und nutze unseren Outreach Composer, um Anschreiben in Sekundenschnelle zu entwerfen.

Über GRID kontaktieren

100% kostenloses Konto · Start in 1 Klick